Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Baxter
Healthtrust
Cerilliant
UBS
McKinsey
Cantor Fitzgerald
Daiichi Sankyo

Generated: September 22, 2018

DrugPatentWatch Database Preview

LATISSE Drug Profile

« Back to Dashboard

Which patents cover Latisse, and when can generic versions of Latisse launch?

Latisse is a drug marketed by Allergan and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

Drug patent expirations by year for LATISSE
Pharmacology for LATISSE
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for LATISSE
Synonyms for LATISSE
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
(5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide
(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
155206-00-1
15M
17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide
17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid
206B001
267244-98-4
5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-
5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-
5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)
AB0015029
ABP000616
AC1NSJUW
AGN 192024
AGN-192024
AK173142
AKOS015995566
AM84507
AN-5283
AQOKCDNYWBIDND-FTOWTWDKSA-N
BDBM220120
Bimataprost [USAN:INN:BAN]
Bimatoprost
Bimatoprost (JAN/USAN/INN)
Bimatoprost (topical, alopecia)
Bimatoprost [USAN:INN:BAN]
Bimatoprost/Lumigan
bimatoprostum
CHEBI:51230
CHEMBL1200963
CS-2085
D02724
D0Q2XF
DB00905
GTPL1958
HY-B0191
I06-1275
I06-1277
Latisse (TN)
LP075849
LS-181817
Lumigan
Lumigan (TN)
M052
MLS006010039
MolPort-006-167-657
NCGC00181745-01
Prostamide
QXS94885MZ
RP17728
SCHEMBL24425
SMR000058996
SR-01000942224
SR-01000942224-1
UNII-QXS94885MZ
US9271961, Bimatoprost
ZINC4474405

US Patents and Regulatory Information for LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for LATISSE
Drugname Dosage Strength RLD Date
➤ Subscribe Topical Solution 0.03% ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for LATISSE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/035 United Kingdom ➤ Try a Free Trial PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
C0033 France ➤ Try a Free Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
00099 Netherlands ➤ Try a Free Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Baxter
Healthtrust
Cerilliant
UBS
McKinsey
Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.